43 related articles for article (PubMed ID: 38598462)
1. Prognostic Impact of Very Small Ground-Glass Opacity Component in Stage IA Solid Predominant Non-small Cell Lung Cancer.
Hattori A; Matsunaga T; Fukui M; Suzuki K; Takamochi K; Suzuki K
Semin Thorac Cardiovasc Surg; 2024 Summer; 36(2):251-260. PubMed ID: 36180013
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of subclassification of stage IIB lung cancer: a retrospective study of 226 patients.
Yin N; Ha M; Liu Y; Gu H; Zhang Z; Liu W
Oncotarget; 2017 Jul; 8(28):45777-45783. PubMed ID: 28501856
[TBL] [Abstract][Full Text] [Related]
3. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.
Al-Sarraf N; Gately K; Lucey J; Aziz R; Doddakula K; Wilson L; McGovern E; Young V
Eur J Cardiothorac Surg; 2008 Oct; 34(4):892-7. PubMed ID: 18722132
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of ground-glass areas within tumours in non-small-cell lung cancer.
Sakurai H; Goto Y; Yoh K; Takamochi K; Shukuya T; Hishida T; Tsuboi M; Yoshida K; Ohde Y; Okumura S; Taguri M; Kunitoh H
Eur J Cardiothorac Surg; 2024 Mar; 65(4):. PubMed ID: 38598462
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer.
Hattori A; Suzuki K; Takamochi K; Wakabayashi M; Aokage K; Saji H; Watanabe SI;
J Thorac Cardiovasc Surg; 2021 Apr; 161(4):1469-1480. PubMed ID: 32451073
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and prognosis of clinical N0 non-small cell lung cancer exceeding 30 mm.
Kagimoto A; Tsutani Y; Handa Y; Mimae T; Miyata Y; Okada M
Jpn J Clin Oncol; 2020 Oct; 50(11):1306-1312. PubMed ID: 32901276
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer.
Watanabe Y; Hattori A; Nojiri S; Matsunaga T; Takamochi K; Oh S; Suzuki K
J Thorac Cardiovasc Surg; 2022 Mar; 163(3):791-801.e4. PubMed ID: 33516459
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer.
Kamigaichi A; Tsutani Y; Mimae T; Miyata Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
Eur J Cardiothorac Surg; 2022 Aug; 62(3):. PubMed ID: 35293580
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set.
Fibla JJ; Cassivi SD; Brunelli A; Decker PA; Allen MS; Darling GE; Landreneau RJ; Putnam JB
Lung Cancer; 2012 Dec; 78(3):259-62. PubMed ID: 23040416
[TBL] [Abstract][Full Text] [Related]
10. Overall Survival with Osimertinib in Resected
Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; Su WC; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Poole L; Bolanos A; Rukazenkov Y; Wu YL;
N Engl J Med; 2023 Jul; 389(2):137-147. PubMed ID: 37272535
[TBL] [Abstract][Full Text] [Related]
11. A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707).
Kunitoh H; Tsuboi M; Wakabayashi M; Okada M; Suzuki K; Watanabe SI; Asamura H;
JTCVS Open; 2020 Dec; 4():90-102. PubMed ID: 36004301
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy.
Shukuya T; Takamochi K; Sakurai H; Yoh K; Hishida T; Tsuboi M; Goto Y; Kudo Y; Ohde Y; Okumura S; Taguri M; Kunitoh H
JTO Clin Res Rep; 2022 May; 3(5):100320. PubMed ID: 35601927
[TBL] [Abstract][Full Text] [Related]
13. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
Saji H; Okada M; Tsuboi M; Nakajima R; Suzuki K; Aokage K; Aoki T; Okami J; Yoshino I; Ito H; Okumura N; Yamaguchi M; Ikeda N; Wakabayashi M; Nakamura K; Fukuda H; Nakamura S; Mitsudomi T; Watanabe SI; Asamura H;
Lancet; 2022 Apr; 399(10335):1607-1617. PubMed ID: 35461558
[TBL] [Abstract][Full Text] [Related]
14. Overview of the ethical guidelines for medical and biological research involving human subjects in Japan.
Eba J; Nakamura K
Jpn J Clin Oncol; 2022 May; 52(6):539-544. PubMed ID: 35349681
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
